|
|
 Previous Article | Table of Contents | Next Article 
High serum interleukin-2 receptor levels are related to advanced disease
and a poor outcome in childhood non-Hodgkin's lymphoma
CH Pui, SH Ip, P Kung, RK Dodge, CW Berard, WM Crist and SB Murphy
The clinical usefulness of serum interleukin-2 receptor (IL2R) measurements
was determined in 59 children with non-Hodgkin's lymphoma (NHL) and six
with B cell acute lymphoblastic leukemia (B-ALL). Levels of the receptor
showed a clear relationship to disease stage, as follows: B-ALL greater
than stage III or IV diffuse small noncleaved- cell NHL greater than stage
III or IV lymphoblastic NHL greater than stage I or II NHL. Soluble IL2R
levels were also closely correlated with serum lactic dehydrogenase levels
(r = 0.7, P = .0001), a recognized indicator of tumor cell burden. Children
with higher soluble IL2R levels (greater than 1,000 U/mL) were
significantly more likely to fail treatment (P = .001), even when the
analysis was limited to those with more advanced disease: stages III and IV
NHL and B-ALL (P = .02). In a multivariate analysis, soluble IL2R level was
found to have greater predictive strength than either serum lactic
dehydrogenase level or disease stage. Thus, the measurement of soluble IL2R
in children with NHL could be expected to improve existing methods of risk
assignment in this disease.
Volume 70,
Issue 3,
pp. 624-628,
09/01/1987
Copyright © 1987 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y. Moon, Y. Kim, M. Kim, J. Lim, C. S. Kang, W. I. Kim, S. I. Shim, N. G. Chung, Y. H. Park, W. S. Min, et al.
Plasma Soluble Interleukin-2 Receptor (sIL-2R) Levels in Patients with Acute Leukemia
Ann. Clin. Lab. Sci.,
October 1, 2004;
34(4):
410 - 415.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Niitsu, J. Okabe-Kado, M. Okamoto, T. Takagi, T. Yoshida, S. Aoki, M. Hirano, and Y. Honma
Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma
Blood,
March 1, 2001;
97(5):
1202 - 1210.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Reiter, M. Schrappe, M. Tiemann, W.-D. Ludwig, E. Yakisan, M. Zimmermann, G. Mann, A. Chott, W. Ebell, T. Klingebiel, et al.
Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored Intensification of Therapy: A Report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90
Blood,
November 15, 1999;
94(10):
3294 - 3306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Niitsu, J. Okabe-Kado, T. Kasukabe, Y. Yamamoto-Yamaguchi, M. Umeda, and Y. Honma
Prognostic Implications of the Differentiation Inhibitory Factor nm23-H1 Protein in the Plasma of Aggressive Non-Hodgkin's Lymphoma
Blood,
November 15, 1999;
94(10):
3541 - 3550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ichikawa, T. Kinoshita, T. Watanabe, H. Kato, H. Nagai, K. Tsushita, H. Saito, and T. Hotta
Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell Lymphoma
N. Engl. J. Med.,
August 21, 1997;
337(8):
529 - 534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Wasik, E. C. Vonderheid, R. D. Bigler, R. Marti, S. R. Lessin, M. Polansky, and M. E. Kadin
Increased Serum Concentration of the Soluble Interleukin-2 Receptor in Cutaneous T-Cell Lymphoma: Clinical and Prognostic Implications
Arch Dermatol,
January 1, 1996;
132(1):
42 - 47.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M.-M. Hsu, J.-Y. Ko, and Y.-L. Chang
Elevated Levels of Soluble Interleukin 2 Receptor and Tumor Necrosis Factor in Nasopharyngeal Carcinoma
Arch Otolaryngol Head Neck Surg,
November 1, 1991;
117(11):
1257 - 1259.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. A. Rubin and D. L. Nelson
The Soluble Interleukin-2 Receptor: Biology, Function, and Clinical Application
Ann Intern Med,
October 15, 1990;
113(8):
619 - 627.
[Abstract]
[PDF]
|
|
|
|
|
